http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2088926-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_776a95a5c992ed7a284d5a4bc1c14591
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-1869
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-1875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-055
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-055
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-543
filingDate 2007-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7fa8e472ccdf23f62411b197c124e4a8
publicationDate 2009-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-2088926-A2
titleOfInvention Imaging of activated vascular endothelium using immunomagnetic mri contrast agents
abstract lmmunomagnetic nanoparticles are used as a contrast agent for enhancing medical diagnostic imaging such as magnetic resonance imaging (MRI). The present invention is directed to methods of making targeted MRI contrast agents from immunomagnetic particles, and to methods of using such MRI contrast agents. Typically, such targeted MRI contrast agents provide enhanced relaxivity, improved signal-to-noise, targeting ability, and resistance to agglomeration. Methods of making such MRI contrast agents typically afford better control over particle size, and methods of using such MRI contrast agents typically can afford enhanced blood clearance rates and distribution. The ability to use the contrast agents im MRI provides a tool in the diagnosis and treatment of several disease states.
priorityDate 2006-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5698271-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6365362-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006171894-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4763
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453759058
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7413
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450540594
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6432052
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID15894
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4618795
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID227317291
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24763304
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406750
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID403975
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID25464
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID55466
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3383
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419520307
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID281839
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454118689
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24838310
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226429255
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450360487
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87575819
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID229780076
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14781

Total number of triples: 43.